

APPENDIX A: HIV Research Articles for Estimating HIV Prevalence Rates  
Among Injection Drug Users 1992-2002 (by MSA and Year)

**1992 Research Articles:**

**Chicago, IL**

Wiebel WW, Johnson W, Ouellet L, et al. Risk behavior and HIV seroincidence among out-of-treatment injection drug users: a four-year prospective study. *Journal of Acquired Immune Deficiency Syndromes*. 1996; 12: 282-289.

**New York City, NY**

Kottiri BJ, Friedman SR, Neaigus A, et al. Risk Networks and Racial/Ethnic Differences in the Prevalence of HIV Infection Among Injection Drug Users. *Journal of AIDS*. 2002; 30: 95-104.

Des Jarlais DC, Perlis TE, Friedman SR, et al. Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991–96. *American Journal of Public Health*. 1998;88:1801–1806.

**Oakland, CA**

California Department of Health Services. Consensus Meeting on HIV/AIDS Incidence and Prevalence in California; Sacramento, Calif. 2001

**San Francisco, CA**

Watters J. Trends in Risk Behavior and HIV Seroprevalence in Heterosexual Injection Drug Users in San Francisco, 1986-1992. *Journal of Acquired Immune Deficiency Syndromes*. 1994; 7: 1276-1281.

Watters JK, Estilo MJ, Kral AH, Lorvick JJ. HIV infection among female injection-drug users recruited in community settings. *Sexually Transmitted Diseases*. 1994; 21: 321-328.

Kral AH, Page-Shafer K, Kellogg T, Riley E, Gee L, Edlin BR, et al. Persistent HIV Incidence among Injection Drug Users in San Francisco During the 1990s: Results of Five Studies. *Journal of Acquired Immune Deficiency Syndromes*. 2004; 37: 1667-1669.

**San Juan, PR**

Deren S, Robles R, Andia J, Colon HM, Kang SY, Perlis T. Trends in HIV seroprevalence and needle sharing among Puerto Rican drug injectors in Puerto Rico and New York: 1992-1999. *Journal of Acquired Immune Deficiency Syndrome*. 2001;26: 164-169.

**1993 Research Articles:**

**Columbus, OH**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

Kral AH, Page-Shafer K, Kellogg T, Riley E, Gee L, Edlin BR, et al. Persistent HIV Incidence among Injection Drug Users in San Francisco During the 1990s: Results of Five Studies. *Journal of Acquired Immune Deficiency Syndromes*. 2004; 37: 1667-1669.

APPENDIX A: HIV Research Articles for Estimating HIV Prevalence Rates  
Among Injection Drug Users 1992-2002 (by MSA and Year)

**Dayton-Springfield, OH**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

**Denver, CO**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. *American Journal of Public Health*. 1998; 88:108-113.

**Detroit, MI**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. *American Journal of Public Health*. 1998; 88:108-113.

**Hartford, CT**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. *American Journal of Public Health*. 1998; 88:108-113.

**Houston, TX**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. *American Journal of Public Health*. 1998; 88:108-113.

Williams ML. "HIV Seroprevalence Among Male IVDUs in Houston, Texas." *American Journal of Public Health*. Vol. 80; 1990, 1507-1509.

**Miami, FL**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. *American Journal of Public Health*. 1998; 88:108-113.

APPENDIX A: HIV Research Articles for Estimating HIV Prevalence Rates  
Among Injection Drug Users 1992-2002 (by MSA and Year)

**New Orleans, LA**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. *American Journal of Public Health*. 1998; 88:108-113.

Bessinger R; Beilke M; Kissinger P; Jarrott C; Tabak OF (1997). Retroviral coinfections at a New Orleans HIV outpatient clinic. *J Acquir Immune Defic Syndr Hum Retrovirol*. 14(1):67-71.

**New York City, NY**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. *American Journal of Public Health*. 1998; 88:108-113.

Des Jarlais DC, Perlis TE, Friedman SR, et al. Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991–96. *American Journal of Public Health*. 1998;88:1801–1806.

**Oakland, CA**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. *American Journal of Public Health*. 1998; 88:108-113.

**Philadelphia, PA**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. *American Journal of Public Health*. 1998; 88:108-113.

**Portland, OR**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

APPENDIX A: HIV Research Articles for Estimating HIV Prevalence Rates  
Among Injection Drug Users 1992-2002 (by MSA and Year)

Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. *American Journal of Public Health*. 1998; 88:108-113.

**Raleigh-Durham, NC**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

**St. Louis, MO**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

**San Antonio, TX**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

**San Francisco, CA**

Kral AH, Page-Shafer K, Kellogg T, Riley E, Gee L, Edlin BR, et al. Persistent HIV Incidence among Injection Drug Users in San Francisco During the 1990s: Results of Five Studies. *Journal of Acquired Immune Deficiency Syndromes*. 2004; 37; 1667-1669.

**San Juan, PR**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. *American Journal of Public Health*. 1998; 88:108-113.

Deren S, Robles R, Andia J, Colon HM, Kang SY, Perlis T. Trends in HIV seroprevalence and needle sharing among Puerto Rican drug injectors in Puerto Rico and New York: 1992-1999. *Journal of Acquired Immune Deficiency Syndrome*. 2001;26: 164-169.

**Tucson, AZ**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. *American Journal of Public Health*. 1998; 88:108-113.

**Washington, DC**

Wang J. Components of Difference in HIV Seropositivity Rate Among Injection Drug Users Between Low- and High-HIV-Prevalence Regions. *AIDS and Behavior*. 2003;7:1-8

APPENDIX A: HIV Research Articles for Estimating HIV Prevalence Rates  
Among Injection Drug Users 1992-2002 (by MSA and Year)

**1994 Research Articles:**

**Baltimore, MD**

Shah NG, Celentano DD, Vlahov D, et al. Correlates of enrollment in methadone maintenance treatment programs differ by HIV-serostatus. *AIDS*. 2000;14:2035–2043.

Murrill CS, Weeks H, Castrucci BC, et al. Age-Specific Seroprevalence of HIV, Hepatitis B Virus, and Hepatitis C Virus Infection Among Injection Drug Users Admitted to Drug Treatment in 6 US Cities. *American Journal of Public Health*.2002; 92: 385-387.

**Denver, CO**

Murrill CS, Weeks H, Castrucci BC, et al. Age-Specific Seroprevalence of HIV, Hepatitis B Virus, and Hepatitis C Virus Infection Among Injection Drug Users Admitted to Drug Treatment in 6 US Cities. *American Journal of Public Health*.2002; 92: 385-387.

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention. 1998

**Detroit, MI**

Murrill CS, Weeks H, Castrucci BC, et al. Age-Specific Seroprevalence of HIV, Hepatitis B Virus, and Hepatitis C Virus Infection Among Injection Drug Users Admitted to Drug Treatment in 6 US Cities. *American Journal of Public Health*.2002; 92: 385-387.

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention; 1998

**New Orleans, LA**

Bessinger R, Beilke M, Kissinger P, Jarrott C, Tabak OF. “Retroviral Coinfections at a New Orleans HIV Outpatient Clinic.” *Journal of AIDS and Human Retrovirology*. Vol. 14; 1997, 67-71.

**New York City, NY**

Des Jarlais DC, Perlis TE, Friedman SR, et al. Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991–96. *American Journal of Public Health*. 1998;88:1801–1806.

**Newark, NJ**

Murrill CS, Weeks H, Castrucci BC, et al. Age-Specific Seroprevalence of HIV, Hepatitis B Virus, and Hepatitis C Virus Infection Among Injection Drug Users Admitted to Drug Treatment in 6 US Cities. *American Journal of Public Health*.2002; 92: 385-387.

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention. 1998

**San Francisco, CA**

APPENDIX A: HIV Research Articles for Estimating HIV Prevalence Rates  
Among Injection Drug Users 1992-2002 (by MSA and Year)

Murrill CS, Weeks H, Castrucci BC, et al. Age-Specific Seroprevalence of HIV, Hepatitis B Virus, and Hepatitis C Virus Infection Among Injection Drug Users Admitted to Drug Treatment in 6 US Cities. *American Journal of Public Health*.2002; 92: 385-387.

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention; 1998

Kral AH, Page-Shafer K, Kellogg T, Riley E, Gee L, Edlin BR, et al. Persistent HIV Incidence among Injection Drug Users in San Francisco During the 1990s: Results of Five Studies. *Journal of Acquired Immune Deficiency Syndromes*. 2004; 37; 1667-1669.

**San Juan, PR**

Deren S, Robles R, Andia J, Colon HM, Kang SY, Perlis T. Trends in HIV seroprevalence and needle sharing among Puerto Rican drug injectors in Puerto Rico and New York: 1992-1999. *Journal of Acquired Immune Deficiency Syndrome*. 2001;26: 164-169.

**Seattle, WA**

Murrill CS, Weeks H, Castrucci BC, et al. Age-Specific Seroprevalence of HIV, Hepatitis B Virus, and Hepatitis C Virus Infection Among Injection Drug Users Admitted to Drug Treatment in 6 US Cities. *American Journal of Public Health*.2002; 92: 385-387.

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention; 1998

**1995 Research Articles:**

**Baltimore, MD**

Garfein, RS, Monterroso, ER, Tong, TC, et al. Comparison of HIV Infection Risk Behaviors Among Injection Drug Users from East and West Coast US Cities. *Journal of Urban Health*. 2004;81: 260-267.

**Chicago, IL**

Ouellet LJ, Thorpe LE, Huo D, et al. Prevalence and incidence of HIV among out-of-treatment injecting drug users, Chicago 1994–96. *Journal of Acquired Immune Deficiency Syndromes*. 2000;25:443–450.

**Los Angeles, CA**

Monterroso ER, Hamburger ME, Vlahov D, Des Jarlais DC, Ouellet LJ, et al. Prevention of HIV Infection in Street-Recruited Injection Drug Users. *Journal of AIDS*. 2000; 25: 63-70.

Lopez-Zetina J, Ford W, Weber M, Barna S, et al. Predictors of syphilis seroreactivity and prevalence of HIV among street recruited injection drug users in LA County, 1994-1996. *Sexually Transmitted Infections*. 2000; 76: 462-469.

**New York City**

APPENDIX A: HIV Research Articles for Estimating HIV Prevalence Rates  
Among Injection Drug Users 1992-2002 (by MSA and Year)

Des Jarlais DC, Perlis TE, Friedman SR, et al. Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991–96. *American Journal of Public Health*. 1998;88:1801–1806.

AIDS in New York State, New York State Department of Health: 2001-02 Edition coverage data reported through December 1999.

**San Diego, CA**

Buchsbaum L, Stafford K, Velasco A. Risk Behavior Study: Injection drug users in San Diego County. County of San Diego Health and Human Services Agency, Office of AIDS Coordination: Summer 1998

**San Francisco, CA**

Kral AH, Page-Shafer K, Kellogg T, Riley E, Gee L, Edlin BR, et al. Persistent HIV Incidence among Injection Drug Users in San Francisco During the 1990s: Results of Five Studies. *Journal of Acquired Immune Deficiency Syndromes*. 2004; 37; 1667-1669.

California Department of Health Services. Consensus Meeting on HIV/AIDS Incidence and Prevalence in California; Sacramento, Calif. 2001

**San Jose, CA**

Monterroso ER, Hamburger ME, Vlahov D, Des Jarlais DC, Ouellet LJ, et al. Prevention of HIV Infection in Street-Recruited Injection Drug Users. *Journal of AIDS*. 2000; 25:63-70.

**1996 Research Articles:**

**Albuquerque, NM**

Doherty SM, Bulterys M. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. *Epidemiology of Infectious Disease*. 2001;127: 475-484.

**Baltimore, MD**

Valente TW, Foreman RK, Junge B, Vlahov D. Needle-Exchange participation, effectiveness and policy: syringe relay, gender, and the paradox of public health. *Journal of Urban Health*. 2001;78:340–349.

**Chicago, IL**

Hasnain, M; Sinacore, J M; Mensah, E K; et al. “Influence of Religiosity on HIV Risk Behaviors in Active Injection Drug Users.” *AIDS Care*. 2005;17: 892-901.

**New York City, NY**

Des Jarlais DC, Perlis TE, Friedman SR, et al. Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991–96. *American Journal of Public Health*. 1998;88:1801–1806.

APPENDIX A: HIV Research Articles for Estimating HIV Prevalence Rates  
Among Injection Drug Users 1992-2002 (by MSA and Year)

AIDS in New York State, New York State Department of Health: 2001-02 Edition  
coverage data reported through December 1999.

**San Antonio, TX**

Zule WA, Desmond DP, Neff JA. Syringe type and drug injector risk for HIV infection: a case study in Texas. *Soc Sci Med*. 2002;55:1103–1113.

**San Francisco, CA**

Kral AH, Page-Shafer K, Kellogg T, Riley E, Gee L, Edlin BR, et al. Persistent HIV Incidence among Injection Drug Users in San Francisco During the 1990s: Results of Five Studies. *Journal of Acquired Immune Deficiency Syndromes*. 2004; 37; 1667-1669.

**San Jose, CA**

Gibson DR, Brand R, Anderson K, Kahn JG, Perales D, Guydish J. Two-to-sixfold decreased odds of HIV risk behavior associated with use of syringe exchange. *Journal of Acquired Immune Deficiency Syndromes*. 2002;31:237–242.

**1997 Research Articles:**

**Atlanta, GA**

Rothenberg R, Baldwin J, Trotter R, Muth S. The risk environment for HIV transmission: results from the Atlanta and Flagstaff network studies. *Journal of Urban Health*. 2001;78:419–431.

**Baltimore, MD**

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention. 1998.

**Boston, MA**

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention. 1998.

**Chicago, IL**

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention. 1998.

**Denver, CO**

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention. 1998.

**Detroit, MI**

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention. 1998.

**Houston, TX**

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention. 1998.



APPENDIX A: HIV Research Articles for Estimating HIV Prevalence Rates  
Among Injection Drug Users 1992-2002 (by MSA and Year)

**Los Angeles, CA**

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention. 1998.

**New York City, NY**

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention. 1998.

Murrill CS, Prevots DR, Miller MS, Linley LA, Royalty JE, Gwinn M. Incidence of HIV among injection drug users entering drug treatment programs in four US cities. *Journal of Urban Health*. 2001;78:152–161.

AIDS in New York State, New York State Department of Health: 2001-02 Edition coverage data reported through December 1999.

**Newark, NJ**

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention; 1998.

Murrill CS, Prevots DR, Miller MS, Linley LA, Royalty JE, Gwinn M. Incidence of HIV among injection drug users entering drug treatment programs in four US cities. *Journal of Urban Health*. 2001;78:152–161.

**Oakland, CA**

Longshore D, Annon J, Anglin MD. HIV prevalence among injection drug users in three northern California communities. *Journal of Acquired Immune Deficiency Syndromes*. 1998;19:200.

**San Francisco, CA**

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention. 1998.

McFarland W, Kellogg TA, Louie B, Murrill C, Katz MH. Low estimates of HIV seroconversions among clients of a drug treatment clinic in San Francisco, 1995–98. *Journal of Acquired Immune Deficiency Syndromes*. 2000;23:426–429.

Longshore D, Annon J, Anglin MD. HIV prevalence among injection drug users in three northern California communities. *Journal of Acquired Immune Deficiency Syndromes*. 1998;19:200.

Kral AH, Page-Shafer K, Kellogg T, Riley E, Gee L, Edlin BR, et al. Persistent HIV Incidence among Injection Drug Users in San Francisco During the 1990s: Results of Five Studies. *Journal of Acquired Immune Deficiency Syndromes*. 2004; 37; 1667-1669.

APPENDIX A: HIV Research Articles for Estimating HIV Prevalence Rates  
Among Injection Drug Users 1992-2002 (by MSA and Year)

Robertson MJ, Clark RA, Charlebois ED, et al. HIV Seroprevalence Among Homeless and Marginally Housed Adults in San Francisco. *American Journal of Public Health*. 2004;94:1207-1217.

**San Juan, PR**

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention. 1998.

**Seattle, WA**

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention. 1998.

Murrill CS, Prevots DR, Miller MS, Linley LA, Royalty JE, Gwinn M. Incidence of HIV among injection drug users entering drug treatment programs in four US cities. *Journal of Urban Health*. 2001;78:152–161.

**Washington, DC**

Centers for Disease Control and Prevention. *National HIV Prevalence Surveys 1997 Summary*. Atlanta, GA. Centers for Disease Control and Prevention. 1998.

**1998 Research Articles:**

**Chicago, IL**

Thorpe L, Bailey S, Huo D, Monterroso E, Ouellet LJ. Injection-related risk behaviors in young urban and suburban injection drug users in Chicago (1997-1999). *Journal of Acquired Immune Deficiency Syndromes* 2001; 27(1):71-78 (3.0)

**Denver, CO**

Kwiatkowski CF, Corsi KF, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. *Social Study of Addiction Alcohol and Other Drugs*. 2002;97:1–6.

**Houston, TX**

Hwang LY, Ross MW, Zack C, Bull L, Rickman K, Holleman M. Prevalence of sexually transmitted infections and associated risk factors among populations of drug abusers. *Clinical Infectious Disease*. 2000;31:920-6.

**Los Angeles, CA**

Lopez-Zetina J, Norton D, Friis R, Rios-Ellis B, Kerndt P. Gender differences in participation in drug treatment among street-recruited injection drug users (IDUs) in Los Angeles County. *XIV International AIDS Conference*. Barcelona, Spain. 2002.

**Miami, FL**

Chitwood DD, Sanchez J, Comerford M, Page JB, McBride DC, Kitner KR. First injection and current risk factors for HIV among new and long-term injection drug users. *AIDS Care*. 2000;12:313–320.

APPENDIX A: HIV Research Articles for Estimating HIV Prevalence Rates  
Among Injection Drug Users 1992-2002 (by MSA and Year)

McCoy CB, Metsch LR, Comerford M, et al. Trends of HIV Risk Behaviors in a Cohort of Injecting Drug Users and their Sex Partners in Miami, Florida, 1988-1998. *AIDS AND BEHAVIOR*. 2005;9:187-199.

**New York City, NY**

AIDS in New York State, New York State Department of Health: 2001-02 Edition coverage data reported through December 1999.

**Providence, RI**

Stein MD, Maksad J, Clarke J: Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. *Drug and Alcohol Dependence*. 2001; 61:211-215.

JG Clarke, MD Stein, L Hanna, M Sobota, JD Rich. Active and Former Injection Drug Users Report of HIV Risk Behaviors During Periods of Incarceration. *Substance Abuse*. 2001, 22:209-216.

**San Antonio, TX**

Zule WA, Desmond DP, Neff JA. Syringe type and drug injector risk for HIV infection: a case study in Texas. *Social Science and Medicine*. 2002;55:1103-1113.

**San Francisco, CA**

Kral AH, Page-Shafer K, Kellogg T, Riley E, Gee L, Edlin BR, et al. Persistent HIV Incidence among Injection Drug Users in San Francisco During the 1990s: Results of Five Studies. *Journal of Acquired Immune Deficiency Syndromes*. 2004; 37; 1667-1669.

**San Juan, PR**

Deren S, Robles R, Andia J, Colon HM, Kang SY, Perlis T. Trends in HIV seroprevalence and needle sharing among Puerto Rican drug injectors in Puerto Rico and New York: 1992-1999. *Journal of Acquired Immune Deficiency Syndrome*. 2001;26: 164-169.

**1999 Research Articles:**

**Chicago, IL**

Bluthenthal RN, Malik MR, Grau LE, Singer M, Marshall P, Heimer, R. Sterile Syringe Access Conditions and Variations in HIV Risk among Drug Injectors in Three Cities. *Addiction*. 2004; 99:136-1146.

**Grand Rapids, MI**

Michigan Department of Public Health. *2002 Profile of HIV/AIDS in Region 5*; Michigan Department of Public Health, Lansing, Mich. 2003

**New York City, NY**

AIDS in New York State, New York State Department of Health: 2001-02 Edition coverage data reported through December 1999.

APPENDIX A: HIV Research Articles for Estimating HIV Prevalence Rates  
Among Injection Drug Users 1992-2002 (by MSA and Year)

**Oakland, CA**

Bluthenthal RN, Malik MR, Grau LE, Singer M, Marshall P, Heimer, R. Sterile Syringe Access Conditions and Variations in HIV Risk among Drug Injectors in Three Cities. *Addiction*. 2004; 99:136-1146.

**San Francisco, CA**

Kral AH, Page-Shafer K, Kellogg T, Riley E, Gee L, Edlin BR, et al. Persistent HIV Incidence among Injection Drug Users in San Francisco During the 1990s: Results of Five Studies. *Journal of Acquired Immune Deficiency Syndromes*. 2004; 37:1667-1669.

**Seattle, WA**

Thiede H, Romero M, Bordelon K, Hagan H, Murrill CS. Using a jail-based survey to monitor HIV and risk behaviors among Seattle area injection drug users. *Journal of Urban Health*. 2001;78:264–278.

**2000 Research Articles:**

**New York City, NY**

Des Jarlais DC, Perlis T, Arasteh K, et al. HIV incidence among injecting drug users in New York City, 1990 to 2002: Use of serologic test algorithm to assess expansion of HIV prevention services. *American Journal of Public Health*. 2005;95:1439-1444.

Deren S, Kang S, Colon HM, et al. HIV Incidence Among High-risk Puerto Rican Drug Users: A Comparison of East Harlem, New York, and Bayamon, Puerto Rico. *Journal of Acquired Immune Deficiency Syndromes*. 2004; 36:1067-74.

**San Diego, CA**

California Department of Health Services. Consensus Meeting on HIV/AIDS Incidence and Prevalence in California; Sacramento, Calif. 2001

**San Francisco, CA**

California Department of Health Services. Consensus Meeting on HIV/AIDS Incidence and Prevalence in California; Sacramento, Calif. 2001.

Kral AH, Page-Shafer K, Kellogg T, Riley E, Gee L, Edlin BR, et al. Persistent HIV Incidence among Injection Drug Users in San Francisco During the 1990s: Results of Five Studies. *Journal of Acquired Immune Deficiency Syndromes*. 2004; 37; 1667-1669.

Bordelon K, Kim A, McFarland W, et al. HIV prevalence, incidence, and related risk behavior among injection drug users upon arrest, San Francisco 1999-2001. *International AIDS Conference*. Barcelona, Spain. 2002

**2001 Research Articles:**

**Fresno, CA**

California Department of Health Services. Consensus Meeting on HIV/AIDS Incidence and Prevalence in California; Sacramento, Calif. 2001

APPENDIX A: HIV Research Articles for Estimating HIV Prevalence Rates  
Among Injection Drug Users 1992-2002 (by MSA and Year)

**Houston, TX**

Bell DC, Montoya ID, Atkinson JS, Yang S. Social Networks and Forecasting the Spread of HIV Infection. *Journal of Acquired Immune Deficiency Syndromes*. 2003;31:218-229

**Los Angeles, CA**

California Department of Health Services. Consensus Meeting on HIV/AIDS Incidence and Prevalence in California; Sacramento, Calif. 2001

**Miami, FL**

Florida Department of Health, Bureau of HIV/AIDS, Summary Report, Data from the HIV Counseling and Testing Database 2001 by County.

[http://www.doh.state.fl.us/disease\\_ctrl/aids/trends/ct/2001Data/2001prelim.html](http://www.doh.state.fl.us/disease_ctrl/aids/trends/ct/2001Data/2001prelim.html).

Downloaded April 9, 2007

**New York City, NY**

Des Jarlais DC, Perlis T, Arasteh K, et al. HIV incidence among injecting drug users in New York City, 1990 to 2002: Use of serologic test algorithm to assess expansion of HIV prevention services. *American Journal of Public Health*. 2005;95:1439-1444.

**Sacramento, CA**

California Department of Health Services. Consensus Meeting on HIV/AIDS Incidence and Prevalence in California; Sacramento, Calif. 2001

**San Francisco, CA**

Kral AH, Page-Shafer K, Kellogg T, Riley E, Gee L, Edlin BR, et al. Persistent HIV Incidence among Injection Drug Users in San Francisco During the 1990s: Results of Five Studies. *Journal of Acquired Immune Deficiency Syndromes*. 2004; 37; 1667-1669.

**Seattle, WA**

Thiede H, Romero M, Bordelon K, Hagan H, Murrill CS. Using a jail-based survey to monitor HIV and risk behaviors among Seattle area injection drug users. *Journal of Urban Health*. 2001;78:264-278.

**2002 Research Articles:**

**San Francisco, CA**

Kral AH, Page-Shafer K, Kellogg T, Riley E, Gee L, Edlin BR, et al. Persistent HIV Incidence among Injection Drug Users in San Francisco During the 1990s: Results of Five Studies. *Journal of Acquired Immune Deficiency Syndromes*. 2004; 37; 1667-1669.